Holen Sie sich die Stockscreener-App
7.90
3.54%
0.27
Handel nachbörslich:
7.91
0.010
+0.13%
Schlusskurs vom Vortag:
$7.63
Offen:
$7.64
24-Stunden-Volumen:
1.98M
Relative Volume:
0.75
Marktkapitalisierung:
$570.79M
Einnahmen:
$161.10M
Nettoeinkommen (Verlust:
$-308.60M
KGV:
-1.6916
EPS:
-4.67
Netto-Cashflow:
$-259.90M
1W Leistung:
+1.28%
1M Leistung:
+7.78%
6M Leistung:
-58.18%
1J Leistung:
-68.21%
1-Tages-Spanne:
$7.53
$8.11
1-Wochen-Bereich:
$7.30
$8.11
52-Wochen-Spanne:
$5.90
$34.11
Arvinas Inc Stock (ARVN) Company Profile
Firmenname
Arvinas Inc
Sektor
Branche
Telefon
203-535-1456
Adresse
395 WINCHESTER AVE, NEW HAVEN, CT
Vergleichen Sie ARVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.90 | 570.79M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Herabstufung | Truist | Buy → Hold |
| 2025-05-02 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-02 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-03-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-01 | Eingeleitet | Goldman | Buy |
| 2023-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-11-20 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-10-23 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-01-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Eingeleitet | Barclays | Overweight |
| 2022-06-21 | Eingeleitet | Jefferies | Hold |
| 2022-05-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-19 | Eingeleitet | Goldman | Buy |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-09 | Eingeleitet | BofA Securities | Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-21 | Eingeleitet | Truist | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-12-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Perform |
| 2019-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-25 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-25 | Eingeleitet | Wedbush | Outperform |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-08-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-22 | Eingeleitet | Citigroup | Buy |
| 2018-10-22 | Eingeleitet | Goldman | Neutral |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Logos Global Management LP Acquires 4,800,000 Shares in Arvinas Inc - GuruFocus
Arvinas (NASDAQ:ARVN) Shares Gap UpWhat's Next? - MarketBeat
Logos Global Management LP Issues a Letter to the Board of Arvinas, Inc. - MarketScreener
Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade - MSN
Arvinas’s SWOT analysis: vepdegestrant efficacy fuels stock potential amid market challenges - Investing.com
Analysts Set Expectations for Arvinas FY2026 Earnings - MarketBeat
ARVN: Arvinas' ARV-393 Shows Promise in Preclinical Lymphoma Stu - GuruFocus
Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma - marketscreener.com
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV- - GuruFocus
Arvinas Unveils Promising ARV-393 Data at EHA Congress - TipRanks
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, - GlobeNewswire
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress - GlobeNewswire Inc.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Arvinas (NASDAQ:ARVN) Stock Price Up 8.7%Here's Why - MarketBeat
Wedbush Predicts Arvinas' FY2026 Earnings (NASDAQ:ARVN) - MarketBeat
Wellington Management Group LLP Has $570,000 Stock Position in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - WV News
Leerink Partnrs Has Strong Estimate for Arvinas Q2 Earnings - MarketBeat
Arvinas (NASDAQ:ARVN) Shares Gap DownHere's Why - MarketBeat
Arvinas and Pfizer seek FDA approval for breast cancer drug By Investing.com - Investing.com South Africa
Arvinas (NASDAQ:ARVN) Stock Rating Lowered by Leerink Partnrs - MarketBeat
Arvinas R&D President Ian Taylor Resigns - TipRanks
Arvinas (ARVN) and Pfizer Submit NDA for Breast Cancer Treatment - GuruFocus
Arvinas Announces Submission of New Drug Application to U.S. FDA - GuruFocus
Will Pfizer Walk Away From Arvinas After PROTAC Disappointment? - insights.citeline.com
Arvinas (ARVN) and Pfizer Submit FDA Application for Breast Canc - GuruFocus
Pfizer, Arvinas seek FDA nod for breast cancer therapy (ARVN) - Seeking Alpha
Arvinas stock rises on FDA submission with Pfizer By Investing.com - Investing.com Nigeria
Arvinas stock rises on FDA submission with Pfizer - Investing.com Australia
Arvinas and Pfizer seek FDA approval for breast cancer drug - Investing.com Australia
Arvinas announces submission of NDA to FDA for vepdegestrant - TipRanks
Arvinas, Pfizer Submit New Drug Application for Vepdegestrant as Breast Cancer Treatment - marketscreener.com
Arvinas (ARVN) and Pfizer Submit NDA for Breast Cancer Treatment | ARVN Stock News - GuruFocus
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer - marketscreener.com
Arvinas Announces Submission of New Drug Application to - GlobeNewswire
What is Wedbush’s Forecast for Arvinas FY2026 Earnings? - Defense World
Q2 Earnings Forecast for Arvinas Issued By Leerink Partnrs - Defense World
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, AR - GuruFocus
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting | ARVN Stock News - GuruFocus
Arvinas, Inc. to Present Preclinical Data on ARV-393, an Investigational PROTAC BCL6 Degrader, at EHA Meeting 2025 - Nasdaq
Arvinas to Present Preclinical Data for PROTAC BCL6 - GlobeNewswire
Breakthrough PROTAC Technology Shows Efficacy Against 3 Types of Aggressive Lymphoma - Stock Titan
Arvinas (NASDAQ:ARVN) Earns Market Perform Rating from Leerink Partners - MarketBeat
Bank of America Corp DE Has $2.47 Million Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
H.C. Wainwright reaffirms buy rating on Arvinas stock after trial data - Investing.com Nigeria
Voloridge Investment Management LLC Buys Shares of 39,063 Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Finanzdaten der Arvinas Inc-Aktie (ARVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):